» Articles » PMID: 17977937

Transplant Estimated Function: a Simple Index to Evaluate Beta-cell Secretion After Islet Transplantation

Overview
Journal Diabetes Care
Specialty Endocrinology
Date 2007 Nov 6
PMID 17977937
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The beta-score is a highly regarded approach to the assessment of transplant functionality. Our aim was to develop an index of beta-cell function that hinges on the pillars of the beta-score (daily insulin requirement and A1C), has a straightforward physiological interpretation, and does not require the execution of an insulin stimulation test.

Research Design And Methods: The new index is denoted transplant estimated function (TEF) and is obtained from the daily insulin requirement and A1C. TEF estimates the amount of insulin secreted daily and can be normalized to the number of transplanted islets, thus permitting evaluation of the cost-effectiveness of the transplant. TEF was compared with the area under the curve of C-peptide [AUC(C-pep)] concentration over 24 h, as well as the acute insulin response to intravenous glucose (AIR(glu)) and to arginine (AIR(arg)). The association between TEF and beta-score was also investigated.

Results: The correlation of TEF with 24-h AUC(C-pep) was r = 0.73 (P < 0.005), whereas that for beta-score versus 24-h AUC(C-pep) was r = 0.33 (NS). The correlation of TEF with AIR(glu) was r = 0.59 (P < 0.001) and close to that for beta-score versus AIR(glu) (r = 0.65, P < 0.001). The correlation of TEF with AIR(arg) was r = 0.33 (P < 0.005) and was similar to that for beta-score versus AIR(arg) (r = 0.34, P < 0.005). TEF and beta-score were correlated well (r = 0.69, P < 0.0001) and showed similar time profiles.

Conclusions: TEF estimates daily insulin secretion, it is simpler than the beta-score, and its performance against reference indexes of beta-cell secretion is in line with that exhibited by beta-score. TEF can be normalized to the number of transplanted islets and thereby provides a benchmarking tool to evaluate the cost-effectiveness of the transplant.

Citing Articles

Status of islet transplantation and innovations to sustainable outcomes: novel sites, cell sources, and drug delivery strategies.

Wong J, Pepper A Front Transplant. 2024; 3:1485444.

PMID: 39553396 PMC: 11565603. DOI: 10.3389/frtra.2024.1485444.


Primary Graft Function and 5 Year Insulin Independence After Pancreas and Islet Transplantation for Type 1 Diabetes: A Retrospective Parallel Cohort Study.

Chetboun M, Masset C, Maanaoui M, Defrance F, Gmyr V, Raverdy V Transpl Int. 2024; 36:11950.

PMID: 38213551 PMC: 10783428. DOI: 10.3389/ti.2023.11950.


Post-Hoc Analysis of a Randomized, Double Blind, Prospective Study at the University of Chicago: Additional Standardizations of Trial Protocol are Needed to Evaluate the Effect of a CXCR1/2 Inhibitor in Islet Allotransplantation.

Bachul P, Golab K, Basto L, Zangan S, Pyda J, Perez-Gutierrez A Cell Transplant. 2021; 30:9636897211001774.

PMID: 33908301 PMC: 8085379. DOI: 10.1177/09636897211001774.


Fasting parameters for estimation of stimulated β cell function in islet transplant recipients with or without basal insulin treatment.

Uitbeijerse B, Nijhoff M, Sont J, de Koning E Am J Transplant. 2020; 21(1):297-306.

PMID: 32524720 PMC: 7818182. DOI: 10.1111/ajt.16135.


Residual β-Cell Function Predicts Clinical Response After Autologous Hematopoietic Stem Cell Transplantation.

Xiang H, Yang C, Xiang T, Wang Z, Ge X, Li F Stem Cells Transl Med. 2016; 5(5):651-7.

PMID: 27025691 PMC: 4835242. DOI: 10.5966/sctm.2015-0144.